News >

Herzog Highlights History and Future of Frontline Ovarian Cancer Care

Caroline Seymour
Published: Thursday, Aug 30, 2018

Thomas Herzog, MD

Thomas Herzog, MD

Clinical trials of intraperitoneal (IP) chemotherapy, hyperthermic intraperitoneal chemotherapy (HIPEC), and dose-dense regimens, while conflicting, have helped evolve the ovarian cancer field in the frontline setting, explained Thomas Herzog, MD.

on Ovarian Cancer, Herzog, professor of Obstetrics and Gynecology, deputy director, University of Cincinnati Cancer Institute, traced the therapeutic evolution of frontline treatment for patients with ovarian cancer.

OncLive: What progress have we seen with frontline therapies in ovarian cancer?

Herzog: We owe all the progress we've made in ovarian cancer to clinical trials. It was those clinical trials over a decade ago that allowed us to adopt paclitaxel into the care of women with ovarian cancer. That has significantly improved survival. Phase III trials have made a difference in taking a very cumbersome inpatient regimen and making it a very convenient outpatient regimen. Those trials allowed us to substitute cisplatin, which had a lot of toxicities with carboplatin, as well as take the paclitaxel infusion time from 24 hours to 3 hours. That's been extremely helpful.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication